Brief: Eris Lifesciences Propose To Demerge Domestic Formulations Business Of Oaknet And Amalgamate It With Co
May 17 (Reuters) - Eris Lifesciences Ltd ERIS.NS :
* PROPOSE TO DEMERGE DOMESTIC FORMULATIONS BUSINESS OF
OAKNET AND
AMALGAMATE IT WITH CO, EFFECTIVE APRIL 1, 2024
* COMMENCED OPERATIONAL INTEGRATION OF BUSINESSES; EXPECTED
TO BE
COMPLETED BY END OF JUNE 2023
* IN-SOURCED MANUFACTURING OF DERMATOLOGY FORMULATIONS AT
GUJARAT
FACILITY TARGETING FROM JAN 2024
Source text for Eikon: ID:nBSE7nbL3S
Further company coverage: ERIS.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eris Lifesciences
See all newsIndia's Eris Lifesciences gains on strong quarterly results
Brief: Eris Lifesciences Sept-Quarter Consol Net Profit 1.84 Billion Rupees
Brief: Eris Lifesciences Says Krishnakumar Vaidyanathan Resigns As Executive Director & COO
Brief: Eris Lifesciences Ltd Says June-Quarter Consol Net Profit 1.42 Billion Rupees
Brief: Eris Lifesciences March-Quarter Consol Net Profit 2.82 Billion Rupees